Cedric Hermans and Glenn Pierce On The Essential Role of A Positive Reinvestment Cycle in Hemophilia
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, shared on LinkedIn:
”Hemophilia stands out among rare diseases for its remarkable therapeutic progress, a success built on decades of innovation, scientific discovery, and investment.
From the cloning of FVIII and FIX genes to the arrival of gene therapy, each milestone has transformed lives.
Global advocacy by WFH, EAHAD, and NBDF has been key to ensuring access and safety.
Yet, sustaining this progress requires continued commitment and investment, so that every person with hemophilia can benefit from the full promise of science.”
Read the full article here.
Article: Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle
Authors: Cedric Hermans, Glenn F Pierce
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines